Patients presented with diverse breast cancer subtypes (luminal, HER2-positive, triple negative), and were managed with various systemic regimens, including endocrine therapy, CDK4/6 inhibitors chemotherapy, anti-HER2 agents or immune checkpoint inhibitor. Here, ERBB2 is linked to breast carcinoma.